+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy

Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy

Journal of Clinical Oncology 16(7): 2409-2416

Purpose: To determine the significance of plasma c-erbB-2 levels to assess the extent of disease spread and to predict the response to chemotherapy in node-positive breast cancer patients. Methods: We determined plasma levels of c-erbB-2 in 79 stages II and III breast cancer patients who received cyclophosphamide, methotrexate, and fluorouracil (CMF)/cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone (CMFVP) chemotherapy. All patients had a minimum follow-up of greater than 60 months or until disease recurrence. Plasma samples were obtained before and after chemotherapy. Plasma c-erbB-2 levels were quantified by enzyme-linked immunoassay. c-erbB-2 levels were analyzed in relation to the patients' axillary lymph node status, menopausal status, disease status, disease-free survival (DFS), and steroid receptor status of tumor. Results: Plasma c-erbB-2 levels varied widely in breast cancer patients. In general, when all patients were included in the analyses, plasma c-erbB-2 levels before chemotherapy correlated significantly with the number of positive axillary lymph nodes and with postchemotherapy c-erbB-2 levels. No association was observed between Pro- or postchemotherapy c-erbB-2 levels and other variables (patients' age at diagnosis, receptor status of the tumor, or disease status). The prognostic significance of different factors (ie, nodal status (one to three v > three positive nodes), menopausal status (Pro- v postmenopausal women), estrogen receptor (ER) status (ER + v ER -), and pre- and postchemotherapy c-erbB-2 levels) in predicting DFS was determined in all study patients. Among the variables examined, nodal status was the strongest predictor of DFS in these patients. The second most significant prognostic marker was postchemotherapy c-erbB-2 level. Prechemotherapy c-erbB-2 levels showed prognostic significance for DFS in a subset of breast cancer patients (ie, patients with > three positive nodes). Patients with greater than three positive lymph nodes and those with greater than 100 fmol/mL of plasma c-erbB-2 levels before therapy had significantly shorter DFS than did those patients with 100 fmol/mL or less c-erbB-2 levels. Conclusion: in breast cancer patients, determination of c-erbB-2 levels before therapy is an important biomarker to assess the extent of disease spread in the lymph nodes. Postchemotherapy c-erbB-2 levels are also a prognostic indicator for DFS in patients who receive chemotherapy. Finally, in a subgroup of patients with greater than three positive nodes, prechemotherapy c-erbB-2 levels are a prognostic marker for response of patients to standard chemotherapy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 009202640

Download citation: RISBibTeXText

PMID: 9667258

DOI: 10.1200/jco.1998.16.7.2409

Related references

Prognostic significance of serum C-erbB-2 levels in hormonally treated advanced breast cancer patients. Anticancer Research 19(6D): 5693-5694, 1999

Clinical Relevance of Soluble c-erbB-2 for Patients with Metastatic Breast Cancer Predicting the Response to Second-Line Hormone or Chemotherapy. Tumor Biology 23(2): 70-75, 2002

Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biology 23(2): 70-75, 2002

Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Research and Treatment 98(3): 241-248, 2006

Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 18(7): 1181-1185, 1991

Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Research & Treatment 40(3): 251-255, 1996

Prognostic significance of circulating C-ErbB-2 in locally advanced breast cancer patients. Tumor Biology 18(SUPPL 1): 97, 1997

Clinical and Prognostic Significance of Preoperative Plasma Fibrinogen Levels in Patients with Operable Breast Cancer. Plos One 11(1): E0146233, 2016

Plasma c-erbB2 levels and response to chemotherapy in breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 212, 1995

Prognostic significance of overexpression of serum c-erbB-2 protein in primary breast cancer patients. Breast 10(Supplement 1): S20, 2001

Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Research 17(1b): 757-760, 1997

Prognostic significance of overexpression of cytosol and serum c-erbB-2 protein in primary breast cancer patients. Breast Cancer Research & Treatment 57(1): 101, 1999

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy. Oncology Reports 29(1): 355-361, 2014

Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. American Journal of Surgery 164(4): 323-326, 1992

Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. Journal of Nuclear Medicine 43(6): 745-751, 2002